SOURCE: Atossa Genetics, Inc.

Atossa Genetics, Inc.

April 16, 2013 08:30 ET

Atossa Genetics to Provide ForeCYTE Breast Health Test to Two Leading Breast Centers in Texas

Important Step Forward in National Rollout of ForeCYTE Test

SEATTLE, WA--(Marketwired - Apr 16, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, will soon begin providing its patented ForeCYTE Breast Health Test for early detection of precursors to breast cancer at two breast centers in Texas: Aurora Breast Center in San Antonio and The Breast Center at Wellness Lubbock in Lubbock. These two breast centers are the first comprehensive breast centers in Texas to offer the ForeCYTE test and represent an important step forward in the Company's quest to make the ForeCYTE test a standard of care nationwide.

The Aurora Breast Center is a leading comprehensive breast care center in San Antonio featuring cutting-edge breast imaging, biopsy and cancer treatment technology and The Breast Center at Wellness Lubbock offers a holistic approach to breast wellness intended to help prevent manageable disease from becoming life-threatening crises. Together, these two clinics serve approximately 5,000 patients annually.

"Dr. Jui-Lien 'Lillian' Chou, M.D., a board-certified radiation oncologist, and her teams in San Antonio and Lubbock know that early detection of precursors to breast cancer can mean the difference between life and death. The Atossa team hopes that other doctors and health centers will follow their lead and join in the crusade for earlier testing for the health and longevity benefit of our sisters, mothers, daughters, wives and friends," said Chris Destro, Vice President.

Dr. Chou, a breast cancer survivor, commented, "Finding and treating precancerous conditions and breast cancer as early as possible is vital. By offering the ForeCYTE Breast Health Test in San Antonio and Lubbock, we are providing women in these areas with a powerful new tool for maintaining their health."

Atossa Genetics' goal is to reduce the stubbornly high rate of breast cancer through the early detection and treatment of the precursor changes that lead to breast cancer. The traditional approach to breast cancer screening is to detect cancer. In addition to cancer detection, Atossa's ForeCYTE test looks earlier in the progression to cancer by detecting reversible, precancerous breast changes.

About the ForeCYTE Breast Health Test

The ForeCYTE Breast Health Test, intended for the 110 million women in the U.S. ages 18-73, is a painless, quick and non-invasive procedure that can be done in a physician's office. A small sample of fluid, aspirated from the nipple of each breast with the Company's patented breast pump, can provide vital early detection of cancer or pre-cancerous conditions that may progress to cancer over an approximately eight year period before cancer can be detected by mammography or other means. The ForeCYTE test is painless, uses no radiation, no invasive biopsy needles and surgical incisions.

Samples obtained by the ForeCYTE method are tested at Atossa's wholly owned National Reference Laboratory for Breast Health, a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.

In addition to the ForeCYTE Breast Health Test, Atossa markets the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.

For additional information, please visit

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with marketing plans, actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its registration statement on Form S-1 filed January 28, 2013, and periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Contact Information


    Atossa Genetics, Inc.
    Chris Destro
    Vice President
    T: (800) 351-3902, Ext. 111
    M: (206) 310-2335
    Email Contact

    Matthew D. Haines (Investors)
    Managing Director
    MBS Value Partners
    (212) 710-9686
    Email Contact